 SAN DIEGO, Dec. 10, 2020 GLOBE NEWSWIRE -- Kura Oncology, Inc. Nasdaq: KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the JMP Securities Hematology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat on Tuesday, December 15, 2020 at 11:00 a.m. ET 8:00 a.m. PT. The virtual forum will be held from December 15-16, 2020. 